Response to Moore and others (2010) and Mehta (2010)
2011

Response to Pneumococcal Serotyping in Laos

publication Evidence: moderate

Author Information

Author(s): Adam L. Cohen, Daniel R. Feikin, Orin S. Levine, Cynthia G. Whitney

Primary Institution: Centers for Disease Control and Prevention; Johns Hopkins Bloomberg School of Public Health

Hypothesis

The data support the use of currently available pneumococcal conjugate vaccines in Asia now, rather than further delays.

Conclusion

Currently available pneumococcal conjugate vaccines cover about three-quarters of all the serotypes causing disease in young children.

Supporting Evidence

  • An estimated 800,000 children died of pneumococcal disease in 2000, with much of the burden in Asia.
  • The World Health Organization recommends that all countries introduce pneumococcal conjugate vaccine into their routine childhood immunization systems.
  • Countries that newly introduce pneumococcal conjugate vaccines will not introduce the 7-valent vaccine, which is being phased out.
  • More than 90 pneumococcal serotypes have been identified, but the 10- and 13-valent vaccines cover the majority of disease-causing serotypes.

Takeaway

This study says we should use the vaccines we have now to help kids in Asia, instead of waiting for better vaccines.

Limitations

The study highlights the lack of high-quality surveillance in developing countries.

Digital Object Identifier (DOI)

10.4269/ajtmh.2011.10-0584

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication